Skip to main content

Pharma News

academics

 

Clinical research courses

  • Astrazeneca withdraws Imfinzi indication in advanced bladder cancer in FDA

    AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made in consultation with the Food and Drug Administration (FDA).

  • Laipac Technology to Launch World’s First AI Rapid Antigen Test System

    The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation.

  • WHO COVID-19 Investigation Is Tainted by Conflict of Interest

    AIDS Healthcare Foundation (AHF) calls for the team that is currently investigating the origins of the novel coronavirus in Wuhan, China to be disbanded and reassembled by a completely independent panel with unfettered access and diplomatic immunity for all members. A conflict of interest of one of the current WHO-sanctioned team members and the tightly choreographed format of the field research cast doubt on the investigation’s credibility and the validity of the eventual findings.

  • New potential therapy for Crohn's disease in children

    Scientists from the Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago demonstrated that a nanotherapy reduces intestinal inflammation and shrinks lesions in a rodent model of severe Crohn's disease. This approach could become an alternative to biologic antibody therapies that carry many side effects, including increased risk of certain cancers. It might also prevent the need for surgery in the future. Findings were published in the journal Advanced Therapeutics.

  • Smiths Detection's BioFlash shown to detect airborne COVID-19

    Smiths Detection, a global leader in threat detection and security screening technologies, reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

  • Celltrion Healthcare receives EC approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, Y

    Celltrion Healthcare announced the European Commission (EC) has granted marketing authorisation for Yuflyma™ (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.

  • Daiichi Sankyo to manufacture AstraZeneca COVID-19 vaccine in Japan

    Daiichi Sankyo Company, Limited is pleased to announce that it recently entered into an outsourcing agreement with AstraZeneca K.K. (hereinafter, AstraZeneca) to manufacture the AstraZeneca-developed COVID-19 vaccine, AZD1222, in Japan.

  • A machine-learning approach to finding treatment options for Covid-19

    When the Covid-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler, a computational biologist in MIT's Department of Electrical Engineering and Computer Science and the Institute for Data, Systems and Society, and an associate member of the Broad Institute of MIT and Harvard. "Really, the only expedient option is to repurpose existing drugs."

  • Aspirin preferred to prevent blood clots in kids after heart surgery : Research

    Aspirin should be favoured over warfarin to prevent blood clotting in children who undergo a surgery that replumbs their hearts, according to a new study.

    The research, led by the Murdoch Children’s Research Institute (MCRI) and published in The Journal of Thoracic and Cardiovascular Surgery, will have implications for clinicians when prescribing blood thinning medications after Fontan surgery, a complex congenital heart disease operation redirecting blood flow from the lower body to the lungs.

  • Government increases budget amount for scientific research and development

    Special provisions have been made in the budget of 2021 to encourage science, technology, innovation and research in the country. This year, the budget of the Department of Science-Technology and Ministry of Earth Sciences has been increased by 30 percent. A total of Rs 16,695 crore has been provided to these two departments in the budget. Giving this information, Science and Technology, Earth Science and Health and Family Welfare Minister Dr. Harsh Vardhan has said that this increase in the budget will encourage research and development.

Subscribe to Pharma News